Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review) DOI Creative Commons
Lunyu Yang,

Yuling Yi,

Zhu Mei

et al.

International Journal of Molecular Medicine, Journal Year: 2025, Volume and Issue: 55(3)

Published: Jan. 23, 2025

Cancer stem cells (CSCs) represent a small, yet pivotal subpopulation of tumor that play significant roles in initiation, progression and therapeutic resistance. Circular RNAs (circRNAs) are distinct class characterized by their closed‑loop structures, lacking 5' to 3'ends. There is growing evidence circRNAs integral the development regulation CSCs. Aberrant expression CSCs can contribute oncogenic properties drug Specifically, modulate CSC behavior via key signaling pathways, thereby promoting self‑renewal maintenance, as well progression. This review summarizes latest research on functional regulatory mechanisms discusses potential applications challenges targeting Understanding intricate interactions between may lead novel strategies effectively combat treatment resistance improve patient outcomes.

Language: Английский

Molecular Pathways of Genistein Activity in Breast Cancer Cells DOI Open Access

Evangelia Konstantinou,

Aristea Gioxari,

Maria Dimitriou

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(10), P. 5556 - 5556

Published: May 20, 2024

The most common malignancy in women is breast cancer. During the development of cancer, oncogenic transcription factors facilitate overproduction inflammatory cytokines and cell adhesion molecules. Antiapoptotic proteins are markedly upregulated cancer cells, which promotes tumor development, metastasis, survival. Promising findings have been found studies on cycle-mediated apoptosis pathway for medication treatment. Dietary phytoconstituents studied great detail their potential to prevent by triggering body’s defense mechanisms. underlying mechanisms action may be clarified considering role polyphenols important signaling pathways. Phenolic acids, flavonoids, tannins, coumarins, lignans, lignins, naphthoquinones, anthraquinones, xanthones, stilbenes examples natural chemicals that being anticancer drugs. These substances also vital This review focuses innovations study polyphenol genistein’s effects cells presents integrated chemical biology methods harness therapeutic advances.

Language: Английский

Citations

22
The role of cancer stem cells in relapse of solid tumors DOI Open Access
Yang Yu

Frontiers in Bioscience-Elite, Journal Year: 2011, Volume and Issue: E4(1), P. 1528 - 1528

Published: Oct. 26, 2011

Recurrence at secondary locations, often years after removal of the primary tumor, accounts for most mortality associated with solid tumors. Metastasis, resistance to chemo- and radiotherapy, eventual relapse have been attributed a distinct tumor subpopulation known as cancer stem cells (CSCs). In this review, we consider properties CSCs that lead these outcomes, in particular relation between epithelial-tomesenchymal transition, stemness, initiation. We compare recent clinical laboratory studies breast cancer, glioblastoma, melanoma illustrate how current anticancer regimens select mesenchymal CSC therefore sow seeds relapse. Finally, discuss emerging paradigm combined therapy targets both non-CSC components.

Language: Английский

Citations

133
Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer DOI
Xiangdong Liu, Bo Luo, Xinhong Wu

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(6), P. 189013 - 189013

Published: Oct. 31, 2023

Language: Английский

Citations

28
Curcumin and nanodelivery systems: New directions for targeted therapy and diagnosis of breast cancer DOI Open Access
Ruhong Zhou,

Jie Gong,

Xianguang Deng

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 180, P. 117404 - 117404

Published: Sept. 21, 2024

Language: Английский

Citations

13
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges DOI Creative Commons
Changyun Li, Wanhe Wang, Chung‐Hang Leung

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: May 20, 2024

Abstract Breast cancer (BC) is the most frequent malignant diagnosis and a primary factor for deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone (PR) human epidermal growth 2 (HER2) triple-negative (TNBC). Based on stages BC, various treatment methods are available with variations rates progression-free disease overall survival patients. However, still faces challenges, particularly terms drug resistance recurrence. study epigenetics has provided new ideas treating BC. Targeting aberrant epigenetic factors inhibitors represents promising anticancer strategy. KDM5 family includes four members, KDM5A, KDM5B, KDM5C, KDMD, all which Jumonji C domain-containing histone H3K4me2/3 demethylases. proteins have been extensively studied where they involved suppressing or promoting depending their specific upstream downstream pathways. Several shown potent inhibitory activity vitro vivo, but challenges exist developing inhibitors. In this review, we introduce current therapeutic options, summarize context-specific functions pathobiology discuss outlook pitfalls disease.

Language: Английский

Citations

9
Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies DOI Creative Commons

Yunhan Tan,

Siyuan Qin, Zhe Zhang

et al.

MedComm – Oncology, Journal Year: 2025, Volume and Issue: 4(1)

Published: Jan. 10, 2025

Abstract The success of cancer therapy has been significantly hampered by various mechanisms therapeutic resistance. Chief among these is the presence clonal heterogeneity within an individual tumor mass. introduction concept stem cells (CSCs)—a rare and immature subpopulation with tumorigenic potential that contributes to intratumoral heterogeneity—has deepened our understanding drug Given characteristics CSCs, such as increased drug‐efflux activity, enhanced DNA‐repair capacity, high metabolic plasticity, adaptability oxidative stress, and/or upregulated detoxifying aldehyde dehydrogenase (ALDH) enzymes, CSCs have recognized a theoretical reservoir for resistant diseases. Implicit in this recognition possibility CSC‐targeted strategies might offer breakthrough overcoming resistance patients. Herein, we summarize generation current underlying CSC‐mediated This extended knowledge progressively translated into novel anticancer enriched available options combination treatments, all which are anticipated improve clinical outcomes patients experiencing CSC‐related relapse.

Language: Английский

Citations

1
The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials DOI Creative Commons
Chen Zhang,

Shu Xu,

Chuanzheng Yin

et al.

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 29, 2025

Breast cancer remains the most frequently diagnosed globally, exerting a profound impact on women's health and healthcare systems. Central to its pathogenesis therapeutic resistance are breast stem cells (BCSCs), which possess unique properties such as self-renewal, differentiation, conventional therapies, contributing tumor initiation, metastasis, recurrence. This comprehensive review elucidates pivotal role of mechanistic target rapamycin (mTOR) pathway in regulating BCSCs implications for progression treatment resistance. We explore cellular mechanisms by mTOR influences metabolism, autophagy, ferroptosis BCSCs, highlighting contribution epithelial-to-mesenchymal transition (EMT), metabolic reprogramming, survival under stress. On molecular level, interacts with key signaling pathways including PI3K/Akt, Notch, IGF-1R, AMPK, TGF-β, well regulatory proteins non-coding RNAs, orchestrating complex network that sustains BCSC mediates chemoresistance radioresistance. The further examines various strategies targeting encompassing selective PI3K/Akt/mTOR inhibitors, monoclonal antibodies, natural products, innovative approaches nanoparticle-mediated drug delivery. Clinical trials investigating inhibitors like sirolimus combination therapies agents everolimus trastuzumab discussed, underscoring their potential eradicating improving patient outcomes. Additionally, compounds repurposed drugs offer promising adjunctive modulating activity BCSC-specific vulnerabilities. In conclusion, presents viable avenue enhancing efficacy effectively eliminating reducing recurrence, overall survival. Continued research clinical validation mTOR-targeted essential translate these insights into effective interventions, ultimately advancing personalized management outcomes patients.

Language: Английский

Citations

1
A promising target for breast cancer: B7-H3 DOI Creative Commons
Ying Jiang, Jiayu Liu, Lingyan Chen

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Feb. 7, 2024

Abstract Breast cancer (BC) is the second-leading factor of mortality for women globally and brought on by a variety genetic environmental causes. The conventional treatments this disease have limitations, making it difficult to improve lifespan breast patients. As result, extensive research has been conducted over past decade find innovative solutions these challenges. Targeting antitumor immune response through immunomodulatory checkpoint protein B7 family revolutionized treatment led intermittent patient responses. B7-H3 recently received attention because its significant demodulation effects in many cancers. Uncontrolled expression bad outlook are strongly associated, according substantial body research. Numerous studies shown that BC expression, induces an evasion phenotype, consequently enhancing survival, proliferation, metastasis, drug resistance cells. Thus, target immunotherapy against may be checkpoint. In review, we discuss structure regulation double costimulatory/coinhibitory function within framework normal physiology. Then expound malignant behavior role tumor microenvironment (TME) finally focus targeted drugs opened new therapeutic opportunities BC.

Language: Английский

Citations

8
PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives DOI Creative Commons

Yalong Qi,

Lixi Li, Yuhan Wei

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 173, P. 116398 - 116398

Published: March 8, 2024

Breast cancer has become the most prevalent malignancy worldwide; however, therapeutic efficacy is far from satisfactory. To alleviate burden of this disease, it imperative to discover novel mechanisms and treatment strategies. Protein phosphatase 2 A (PP2A) comprises a family mammalian serine/threonine phosphatases that regulate many cellular processes. PP2A dysregulated in several human diseases, including oncological pathologies, plays pivotal role initiation progression tumours. The as tumour suppressor been extensively studied, its regulation can serve target for anticancer therapy. Recent studies have shown promotor. PP2A-mediated therapy may involve two opposing mechanisms: activation inhibition. In general, contradictory roles should not be overlooked, more work needed determine molecular mechanism by which affects review, literature on tumours, especially breast cancer, was analysed. This review describes relevant targets such cell cycle control, DNA damage responses, epidermal growth factor receptor, immune modulation death resistance, lead effective strategies or influence drug development cancer.

Language: Английский

Citations

7
Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo DOI Creative Commons

Qi-xuan Huang,

Da-meng Fan,

Zaozao Zheng

et al.

Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 67(8), P. 6658 - 6672

Published: April 3, 2024

BRD4 is associated with a variety of human diseases, including breast cancer. The crucial roles amino-terminal bromodomains (BDs) in binding acetylated histones to regulate oncogene expression make them promising drug targets. However, adverse events impede the development BD inhibitors. adopts an extraterminal (ET) domain, which recruits proteins drive expression. We discovered peptide inhibitor PiET targeting ET domain disrupt BRD4/JMJD6 interaction, protein complex critical and cell-permeable form PiET, TAT-PiET, PROTAC-modified TAT-PiET-PROTAC, potently inhibits target genes cancer cell growth. Combination therapy TAT-PiET/TAT-PiET-PROTAC JQ1, iJMJD6, or Fulvestrant exhibits synergistic effects. TAT-PiET TAT-PiET-PROTAC treatment overcomes endocrine resistance ERα-positive cells. Taken together, we demonstrated that effective suppressing cancer, providing therapeutic avenue clinic.

Language: Английский

Citations

6